Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.
Q4 2025 Management View Jennifer Good, CEO, reported that "2025 was a major inflection point for growth at Trevi, driven by our positive data readouts in both the CORAL trial in patients with ...
United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary ...
Researchers from the US identified transcriptomic differences related to sex in patients with idiopathic pulmonary fibrosis.
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
IPF has an insidious onset. It often presents with persistent dry cough associated with worsening breathlessness and progressive decline in one's exercise capacity. Hemoptysis (coughing up blood) is ...
What is Idiopathic Pulmonary Fibrosis (IPF)? IPF is a chronic, progressive, lung disease characterized by disabling shortness of breath, declining exercise capacity and extensive formation of scar ...
Add Yahoo as a preferred source to see more of our stories on Google. German pharma Boehringer Ingelheim has obtained FDA approval for its disease-modifying therapy Boehringer Ingelheim’s Jascayd ...
The actor tells AARP about her mom’s struggle with pulmonary fibrosis and the warning signs that might help others get an earlier diagnosis ...
Editor's Note: Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause, affecting mostly older adults. Confined to the lungs, the disease causes lung tissue to become thick and scarred over ...
What is idiopathic pulmonary fibrosis (IPF)? Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease that affects approximately 3 million people worldwide. Despite the condition ...